Correction to: Claspin Overexpression Promotes Tumor Progression and Predicts Poor Clinical Outcome in Prostate Cancer by Chao Cai et al . Genet Test Mol Biomarkers 2021;25:131-139. DOI: 10.1089/gtmb.2020.0226

In the February 2021 issue of Genetic Testing and Molecular Biomarkers (vol. 25, no. 2: 131-139), the article entitled Claspin Overexpression Promotes Tumor Progression and Predicts Poor Clinical Outcome in Prostate Cancer requires correction. A revision to the Ethics Approval and Consent to Participate section was erroneously omitted.

The section originally read:

“The experimental procedures of this study were proved by the Ethics Committee of Affiliated Hospital of Weifang Medical University. Informed consent for the sample collection and application was signed by each participant.”

The revised now reads:

“The experimental procedures of the current study were approved by the Ethics Committee of The First Affiliated Hospital of Guangzhou Medical University. The informed consent for the sample collection and application was signed by each participant.”

The online version has been corrected to reflect this. The publisher apologizes for this error.